Comparison and analysis of the efficacy and safety of DOX and mFOLFOX6 in neoadjuvant chemotherapy for gastric cancer / 中国医师杂志

ABSTRACT

Objective To compare the efficacy and safety of DOX (docetaxel + oxaliplatin + capecitabine) program with mFOLFOX6 (oxaliplatin + fluorouracil) program as neoadjuvant chemotherapy in locally advanced gastric cancer patients.Methods 72 patients who was diagnosed as local advanced gastric cancer in our hospital from October 2014 to December 2017,were treated by neoadjuvant chemotherapy,36 of which were mFOLFOX6,and 36 were DOX.After 3 cycles of chemotherapy,the clinical efficacy was determined and the adverse reactions were analyzed.Results In the 36 cases of mFOLFOX6 group,the clinical remission rate was 27.8％ (10/36),and the tumor control rate was 63.9％ (23/36).Among the 36 patients in the DOX group,the clinical remission rate was 36.1％ (13/36),and the tumor control rate was 75.0％ (27/36).The recent clinical efficacy of the two groups were not statistically significant (both P ＞ 0.05).The R0 cutting rate of mFOLFOX6 group was 66.7％ (24/36),and the DOX group was 77.8％ (28/36).There was no statistically significant difference between the R0 cut rate of the radical operation of the two groups (both P ＞ 0.05).The incidence of nausea,vomiting and leukocyte reduction in DOX group was significantly higher than that in the mFOLFOX6 group,and the difference was statistically significant (all P ＜ 0.05).Conclusions The combination of mFOLFOX6 and DOX is similar in the treatment of neoadjuvant chemotherapy in gastric cancer,but the incidence of gastrointestinal reaction and hematological toxicity in DOX scheme is higher.